---
title: "Ambey Laboratories Ltd (AMBEY) — Share Price, Financials & Analysis"
symbol: "AMBEY"
company: "Ambey Laboratories Ltd"
canonical: "https://tapetide.com/stocks/AMBEY"
isin: "INE0M3I01029"
nse_symbol: "DHANSA"
sector: "Chemicals"
industry: "Pesticides & Agrochemicals"
market_cap_cr: 91.61
generated_at: "2026-09-13T19:02:42.780Z"
---

# Ambey Laboratories Ltd (AMBEY)

Canonical page: https://tapetide.com/stocks/AMBEY

## Company

- **NSE Symbol:** DHANSA
- **ISIN:** INE0M3I01029
- **Sector:** Chemicals
- **Industry:** Pesticides & Agrochemicals
- **Macro Sector:** Commodities
- **Stock Type:** EQUITY
- **Listed Since:** 2024-07-11
- **Face Value:** ₹10
- **F&O Eligible:** No
- **Website:** ambeylab.com

## About

Incorporated in 1985, Ambey Laboratories Ltd is in the business of manufacturing and distribution of agro and home hygiene products.[1]

## Latest Price

- **Price:** ₹35.75
- **Change:** +1.7 (+4.99%)
- **Open:** ₹35.45
- **Day High:** ₹35.75
- **Day Low:** ₹35.45
- **Previous Close:** ₹34.05
- **Volume:** 26000
- **As Of:** 2026-09-11T09:31:29+00:00

## Key Fundamentals

Observed at 2026-09-11T04:41:01.627516Z.

- **Market Cap:** ₹91.61 Cr
- **Classification:** SME
- **P/E (reported):** 16.6
- **Book Value:** ₹40.09
- **Price to Book:** 0.85
- **Dividend Yield:** 0%
- **ROE:** 6.26%
- **ROCE:** 10.21%
- **Debt to Equity:** 0.54
- **Revenue (yearly):** ₹141.54 Cr
- **Net Income:** ₹5.69 Cr
- **EBITDA:** ₹10.92 Cr
- **52-Week High:** ₹47
- **52-Week Low:** ₹16.2
- **RSI (14):** 81.95

## Tapetide Score

- **Score:** 42 / 100
- **Score date:** 2026-09-04
- **Archetype:** Trend Ahead of Fundamentals
- **What it means:** The price trend is running ahead of what the financials currently support. Moves like this depend on the fundamentals catching up; check what would have to be true for that.
- **Pillar profile:** Quality: Weak · Valuation: Expensive · Momentum: Rising
- **Percentile:** 19.7 (of 4473 scored stocks)
- **Confidence:** 98%
- **Data coverage:** 95%

| Pillar | Score | Weight |
| --- | --- | --- |
| financial health | 50.12 | 9% |
| growth | 39.23 | 9% |
| momentum | 72.26 | 12% |
| ownership | 44.89 | 24% |
| quality | 29.61 | 22% |
| valuation | 40.66 | 24% |

The Tapetide Score is decision-support only, not investment advice.

## Key Insights

### Strengths

- Stock is trading at 0.68 times its book value

### Weaknesses

- Though the company is reporting repeated profits, it is not paying out dividend
- Debtor days have increased from 60.5 to 112 days.
- Working capital days have increased from 64.4 days to 126 days

## Growth Rates

| Metric | QoQ | 1Y | 3Y | 5Y |
| --- | --- | --- | --- | --- |
| cash flow growth | — | -162.21% | -443.08% | — |
| ebitda margin growth | -18.18% | -11.59% | -12.6% | -40.16% |
| net income growth | -65% | 18.54% | 10% | 58.06% |
| revenue growth | -26.09% | 6.26% | 16% | 10.71% |
| roce | — | -37.05% | -56.33% | 20.88% |
| roe | — | -74.45% | 19.38% | -104.76% |

## Financial Statements

### Quarterly Results

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2024 | Sep 2024 | Mar 2025 | Sep 2025 |
| --- | --- | --- | --- | --- |
| Sales | 60 | 68 | 64 | 68 |
| Expenses | 56 | 62 | 60 | 62 |
| Operating Profit | 4 | 6 | 4 | 6 |
| OPM % | 7 | 9 | 6 | 9 |
| Other Income | 1 | 1 | 1 | 0 |
| Interest | 1 | 2 | 1 | 1 |
| Depreciation | 1 | 1 | 2 | 2 |
| Profit before tax | 3 | 4 | 2 | 3 |
| Tax % | 33 | 18 | 25 | 13 |
| Net Profit | 2 | 3 | 2 | 3 |
| EPS in Rs | 0.94 | 1.19 | 0.73 | 1.05 |

### Profit & Loss

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
| --- | --- | --- | --- | --- | --- | --- |
| Sales | 82 | 85 | 105 | 120 | 131 | 132 |
| Expenses | 72 | 74 | 97 | 111 | 122 | 122 |
| Operating Profit | 10 | 10 | 8 | 9 | 10 | 10 |
| OPM % | 12 | 12 | 7 | 8 | 7 | 7 |
| Other Income | 1 | 1 | 3 | 1 | 2 | 1 |
| Interest | 4 | 3 | 2 | 2 | 3 | 2 |
| Depreciation | 3 | 3 | 3 | 2 | 3 | 4 |
| Profit before tax | 3 | 5 | 6 | 6 | 6 | 5 |
| Tax % | -235 | 26 | 5 | -40 | 21 | — |
| Net Profit | 10 | 4 | 5 | 8 | 5 | 4 |
| EPS in Rs | 211.28 | 20.11 | 29.52 | 4.13 | 1.92 | 1.78 |
| Dividend Payout % | 0 | 0 | 0 | 0 | 0 | — |

### Balance Sheet

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
| --- | --- | --- | --- | --- | --- | --- |
| Equity Capital | 5 | 18 | 18 | 19 | 25 | 25 |
| Reserves | -13 | 1 | 1 | 13 | 51 | 67 |
| Borrowings | 33 | 18 | 14 | 30 | 41 | 40 |
| Other Liabilities | 20 | 19 | 21 | 18 | 10 | 9 |
| Total Liabilities | 45 | 56 | 54 | 79 | 127 | 140 |
| Fixed Assets | 16 | 25 | 25 | 24 | 23 | 22 |
| CWIP | 1 | 0 | 0 | 4 | 16 | 17 |
| Investments | 0 | 0 | 1 | 1 | 0 | 0 |
| Other Assets | 28 | 31 | 28 | 51 | 88 | 101 |
| Total Assets | 45 | 56 | 54 | 79 | 127 | 140 |

### Cash Flow

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
| --- | --- | --- | --- | --- | --- |
| Cash from Operating Activity | 3 | 6 | 10 | -13 | -34 |
| Cash from Investing Activity | -1 | -1 | -4 | -5 | -14 |
| Cash from Financing Activity | -1 | -5 | -6 | 18 | 48 |
| Net Cash Flow | 0 | 0 | 0 | 0 | 0 |
| Free Cash Flow | 2 | 5 | 7 | -18 | -48 |
| CFO/OP | 23 | 47 | 120 | -131 | -347 |

### Ratios

| Item | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
| --- | --- | --- | --- | --- | --- |
| Debtor Days | 31 | 37 | 12 | 57 | 112 |
| Inventory Days | — | — | 78 | 75 | 99 |
| Days Payable | — | — | 74 | 54 | 22 |
| Cash Conversion Cycle | 31 | 37 | 17 | 78 | 189 |
| Working Capital Days | -10 | 11 | 18 | 49 | 126 |
| ROCE % | — | 25 | 22 | 18 | 10 |

## Shareholding Pattern

### Quarterly

| Category | Sep 2024 | Mar 2025 | Sep 2025 | Mar 2026 | Jun 2026 |
| --- | --- | --- | --- | --- | --- |
| Promoters | 69.9% | 70.11% | 70.15% | 70.15% | 65.05% |
| FIIs | 1.46% | 0% | 0% | 0% | 0% |
| DIIs | 0% | 0% | 0% | 0.72% | 0% |
| Government | 0% | 0% | 0% | 0% | 0% |
| Public | 20.28% | 22.4% | 22.36% | 22.81% | 26.58% |
| Others | 8.36% | 7.5% | 7.49% | 6.32% | 8.37% |
| No. of Shareholders | 1520 | 1327 | 1291 | 1224 | 1201 |

## Technical Indicators

Derived from daily closing prices and recomputed each trading session; values move with the market.

- **Overall Signal:** Strong Buy
- **Buy / Neutral / Sell:** 13 / 1 / 5

### Moving Averages — summary: **Strong Buy**

| Indicator | Value | Signal |
| --- | --- | --- |
| SMA (10) | 29.78 | Buy |
| EMA (10) | 30.38 | Buy |
| SMA (20) | 26.1 | Buy |
| EMA (20) | 27.52 | Buy |
| SMA (50) | 23.35 | Buy |
| EMA (50) | 24.99 | Buy |
| SMA (100) | 24.47 | Buy |
| EMA (100) | 25.47 | Buy |
| SMA (200) | 29.5 | Buy |
| EMA (200) | 29.08 | Buy |

### Oscillators — summary: **Strong Sell**

| Indicator | Value | Signal |
| --- | --- | --- |
| RSI (14) | 84.03 | Sell |
| MACD (12,26,9) | 3.09 | Buy |
| Stochastic (14,3,3) | 100 | Sell |
| ADX (14) | 43.35 | Buy |
| Williams %R (14) | 0 | Sell |
| ATR (14) | 1.33 | High Volatility |
| ROC (12) | 51.16 | Buy |
| Stoch RSI (14) | 100 | Sell |
| UO (7,14,28) | 92.61 | Sell |

## Filings & Documents

### Other Documents

| Date | Document |
| --- | --- |
| 8 May 2026 - Wholly owned subsidiary acquired 14.32 bigha land in Rajasthan for biogas pellet project for Rs. 93.09 lakh. | [General Updates 8 May 2026 - Wholly owned subsidiary acquired 14.32 bigha land in Rajasthan for biogas pellet project for Rs. 93.09 lakh.](https://nsearchives.nseindia.com/corporate/AMBEY_08052026130729_Intimation_under_Regulation_30_Land_Acquisition.pdf) |
| 6 March 2026 - Company name changed from Ambey Laboratories Limited to Dhansa Labs Limited effective March 6, 2026. | [Name Change 6 March 2026 - Company name changed from Ambey Laboratories Limited to Dhansa Labs Limited effective March 6, 2026.](https://nsearchives.nseindia.com/corporate/AMBEY_06032026181817_Intimation_name_change.pdf) |
| 6 June 2026 - Audio recording of 5 June 2026 earnings call for Q4 and FY2025-26 results uploaded. | [Analysts/Institutional Investor Meet/Con. Call Updates 6 June 2026 - Audio recording of 5 June 2026 earnings call for Q4 and FY2025-26 results uploaded.](https://nsearchives.nseindia.com/corporate/AMBEY_06062026182336_IntimationEarningscall.pdf) |
| 6 April 2026 - Promoters disclosed non-encumbrance on 1,74,99,420 shares for FY ended 31 March 2026. | [Updates 6 April 2026 - Promoters disclosed non-encumbrance on 1,74,99,420 shares for FY ended 31 March 2026.](https://nsearchives.nseindia.com/corporate/AMBEY_06042026163731_Annual_Disclosure_SAST_31_4_.pdf) |
| 5 June 2026 - FY26 audited results: revenue ₹141.54 crore, EBITDA ₹12.22 crore, PAT ₹5.52 crore; expansion and CBG projects outlined. | [Investor Presentation 5 June 2026 - FY26 audited results: revenue ₹141.54 crore, EBITDA ₹12.22 crore, PAT ₹5.52 crore; expansion and CBG projects outlined.](https://nsearchives.nseindia.com/corporate/AMBEY_05062026165638_Investor_Presentation.pdf) |
| 4 February 2026 - 9 Jan 2026: Clarifies first-time consolidated comparatives and says issue proceeds utilisation covered in limited review. | [Reply to Clarification- Financial results 4 February 2026 - 9 Jan 2026: Clarifies first-time consolidated comparatives and says issue proceeds utilisation covered in limited review.](https://nsearchives.nseindia.com/corporate/AMBEY_09012026125624_NSE_clarification_signed.pdf) |
| 31 May 2026 - Newspaper advertisement for Q4, half-year and FY2026 standalone/consolidated financial results published on May 31, 2026. | [Copy of Newspaper Publication 31 May 2026 - Newspaper advertisement for Q4, half-year and FY2026 standalone/consolidated financial results published on May 31, 2026.](https://nsearchives.nseindia.com/corporate/AMBEY_31052026155038_Intimation_for_Newspaper_advt_31052026_signed.pdf) |
| 30 May 2026 - Board approved audited FY26 standalone and consolidated results; auditors issued unmodified opinion. | [Outcome of Board Meeting 30 May 2026 - Board approved audited FY26 standalone and consolidated results; auditors issued unmodified opinion.](https://nsearchives.nseindia.com/corporate/AMBEY_30052026000624_Outcome_of_BM.pdf) |
| 29 May 2026 - SDD compliance certificate filed for FY26; 228 events captured, with minor entry delays and duplicate records. | [Structural Digital Database 29 May 2026 - SDD compliance certificate filed for FY26; 228 events captured, with minor entry delays and duplicate records.](https://nsearchives.nseindia.com/corporate/AMBEY_29052026135036_SDD_Compliance_Certificate.pdf) |
| 28 March 2026 - WOS secured Rs84.82 crore loan for Rs120 crore CBG plant; tripartite offtake with GAIL and Torrent Gas (27-03-2026). | [Agreements 28 March 2026 - WOS secured Rs84.82 crore loan for Rs120 crore CBG plant; tripartite offtake with GAIL and Torrent Gas (27-03-2026).](https://nsearchives.nseindia.com/corporate/AMBEY_28032026155040_Intimation_under_regulation_30_signed.pdf) |

### Annual Reports

| Date | Document |
| --- | --- |
| from nse | [Financial Year 2025 from nse](https://archives.nseindia.com/annual_reports/SME_AR_28467_AMBEY_2024_2025_A_4740905_04092025190011.pdf) |
| from nse | [Financial Year 2024 from nse](https://archives.nseindia.com/annual_reports/SME_AR_26178_AMBEY_2023_2024_07092024195044.pdf) |
| from nse | [Financial Year 2013 from nse](https://archives.nseindia.com/annual_reports/AR_1316_SUJANAUNI_2012_2013_02092013110359.zip) |
| from nse | [Financial Year 2011 from nse](https://archives.nseindia.com/annual_reports/AR_SUJANAUNI_2009_2011_15062012101456.zip) |
| from bse | [Financial Year 2020 from bse](https://www.bseindia.com/bseplus/AnnualReport/517224/68188517224.pdf) |
| from bse | [Financial Year 2019 from bse](https://www.bseindia.com/bseplus/AnnualReport/517224/5172240319.pdf) |
| from bse | [Financial Year 2018 from bse](https://www.bseindia.com/bseplus/AnnualReport/517224/5172240318.pdf) |
| from bse | [Financial Year 2017 from bse](https://www.bseindia.com/bseplus/AnnualReport/517224/5172240317.pdf) |
| from bse | [Financial Year 2016 from bse](https://www.bseindia.com/bseplus/AnnualReport/517224/5172240316.pdf) |
| from bse | [Financial Year 2015 from bse](https://www.bseindia.com/bseplus/AnnualReport/517224/5172240315.pdf) |

---

Provenance differs by section. Financial statements, shareholding and filings are as reported in company disclosures to NSE/BSE/SEBI. Price, volume and 52-week levels are exchange market data. Technical indicators are computed by Tapetide from daily closing prices. The Tapetide Score is Tapetide's own analysis. Analyst ratings are third-party estimates, not company statements. All figures are for research and information only and are not investment advice. Generated 2026-09-13T19:02:42.780Z.